Verus Capital Partners LLC Invests $51,000 in Rockwell Medical, Inc. (NASDAQ:RMTI)

Verus Capital Partners LLC bought a new stake in shares of Rockwell Medical, Inc. (NASDAQ:RMTI) during the 3rd quarter, Holdings Channel.com reports. The firm bought 12,800 shares of the company’s stock, valued at approximately $51,000.

A number of other institutional investors have also recently added to or reduced their stakes in RMTI. Armistice Capital LLC raised its position in Rockwell Medical by 22.5% in the second quarter. Armistice Capital LLC now owns 3,221,640 shares of the company’s stock valued at $5,670,000 after purchasing an additional 592,000 shares during the period. Renaissance Technologies LLC grew its stake in shares of Rockwell Medical by 877.1% in the second quarter. Renaissance Technologies LLC now owns 102,700 shares of the company’s stock valued at $181,000 after buying an additional 92,189 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Rockwell Medical by 4.0% during the 1st quarter. Vanguard Group Inc. now owns 1,118,277 shares of the company’s stock valued at $1,856,000 after buying an additional 43,302 shares during the period. Beacon Financial Advisory LLC acquired a new position in Rockwell Medical during the 3rd quarter worth approximately $98,000. Finally, Concurrent Investment Advisors LLC purchased a new position in Rockwell Medical in the 3rd quarter worth approximately $40,000. 23.31% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $9.00 price objective on shares of Rockwell Medical in a research note on Wednesday, September 11th. StockNews.com upgraded shares of Rockwell Medical from a “hold” rating to a “buy” rating in a report on Wednesday.

Rockwell Medical Price Performance

Shares of NASDAQ RMTI opened at $2.63 on Thursday. The company has a quick ratio of 1.60, a current ratio of 2.00 and a debt-to-equity ratio of 0.41. Rockwell Medical, Inc. has a fifty-two week low of $1.16 and a fifty-two week high of $5.15. The business has a 50 day moving average price of $3.72 and a two-hundred day moving average price of $2.60. The firm has a market cap of $81.61 million, a PE ratio of -52.60 and a beta of 1.50.

Rockwell Medical (NASDAQ:RMTI) last released its earnings results on Tuesday, November 12th. The company reported $0.05 EPS for the quarter, beating the consensus estimate of $0.01 by $0.04. The company had revenue of $28.32 million during the quarter, compared to analysts’ expectations of $25.99 million. Rockwell Medical had a positive return on equity of 9.27% and a negative net margin of 1.25%. Sell-side analysts expect that Rockwell Medical, Inc. will post -0.03 earnings per share for the current fiscal year.

Rockwell Medical Profile

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.